Outsourcing Pharma presents its weekly round-up of the latest new faces and appointments in the pharmaceutical industry, including news from Patheon, CTI and PRECOS.
Outsourcing-Pharma presents its weekly round-up of the latest changes on the pharmaceutical career ladder, including news from Patheon, Wolfe Laboratories, and Premier Research.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a new role for former Genzyme CEO and a leadership change at Astellas Europe.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Catalent, Cytel and Laureate Biopharmaceutical.
Charles River Laboratories (CRL) has added two new exclusive knockout rats to its preclinical development offering in deal with Transposagen Biopharmaceuticals.
Regulus Therapeutics’ microRNA satellite technology has won the firm its biggest deal to date with French drugmaker Sanofi-Aventis agreeing a development accord worth up to $750m (€606m).
US CMO Florida Biologix (FB) says its new contract with America Stem Cell (ASC) shows that demand for trial-phase biologics manufacturing is starting to recover.
Wacker has brought its expanded cyclodextrin facility online following its $21m (€15m) expansion, which has significantly increased capacity in response to growing demand for the excipient.
AstraZeneca (AZ) has become the latest company to enter into a research collaboration with Jubilant, with the companies initially focusing on delivering preclinical candidates in the neuroscience area.
The use of disposable manufacturing equipment in pharmaceutical
production and greater need for containment equipment were
recurring themes at the Interphex show in Philadelphia last week,
and both were addressed by new equipment...
The contract manufacturing market for biologicals will more than
double over the next six years, but production costs are higher
than necessary because 'downstream' processing is being ignored.
KS Avicenna, the Canadian unit of KS Biomedix of the UK, launched a
newly expanded contract biopharmaceutical manufacturing facility in
Canada, to service both North American and European clients, at the
start of the BIO 2003 meeting,...
The bulk of biotech companies are firmly rooted towards the foot of
the ladder of corporate evolution. Precious few can realistically
claim to be at the top end of the evolutionary scale with full
R&D capabilities, global reach...